A phase IV, randomised, double-blind, controlled, parallel group trial to evaluate the effectiveness and safety of Balneum Plus versus emollient in the treatment of chronic kidney disease-associated pruritus in haemodialysis patients.
clinical trial
haemodialysis
pruritus
quality of life
therapy
Journal
Clinical kidney journal
ISSN: 2048-8505
Titre abrégé: Clin Kidney J
Pays: England
ID NLM: 101579321
Informations de publication
Date de publication:
Aug 2023
Aug 2023
Historique:
received:
24
10
2022
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
Chronic kidney disease-associated pruritus (CKD-aP) is a common, distressing complaint in patients with advanced renal disease that is frequently overlooked. Treatment is often unsatisfactory. Balneum Plus (Almirall, Barcelona, Spain) is a cream containing 3% lauromacrogols and 5% urea, commonly used to treat atopic dermatitis. It has not been studied in CKD-aP to date. Adult haemodialysis patients were randomised 1:1 to apply Balneum Plus or E45 (Reckitt Beckiser, Slough, UK) to compare the active ingredients of lauromacrogol and urea with a control cream. Itch was defined as three episodes of itching during the last 2 weeks, appearing a few times a day, lasting a few minutes and troubling the patient [1]. Patients with other causes of itch, e.g. eczema and liver disease, were excluded. The primary outcome was a reduction in itch as measured by the visual analogue scale (VAS) score at 4 weeks and analysed using an analysis of covariance approach. A total of 314 patients were screened and 58 patients were randomised, 29 in each group. Three patients dropped out in each group. The median baseline VAS scores were 6.5 [interquartile range (IQR) 4.4-8.0] in the Balneum Plus group and 6.3 (IQR 5.1-7.3) in the E45 group. After 4 weeks, VAS scores decreased to 2.6 (IQR 0.9-4.5) and 2.0 (IQR 0.5-4.8) in the Balneum Plus and E45 groups respectively ( This is the first randomised controlled study of two different emollients for the treatment of CKD-aP and is a negative study. We found no significant difference in itch scores between Balneum Plus and E45.
Sections du résumé
Background
UNASSIGNED
Chronic kidney disease-associated pruritus (CKD-aP) is a common, distressing complaint in patients with advanced renal disease that is frequently overlooked. Treatment is often unsatisfactory. Balneum Plus (Almirall, Barcelona, Spain) is a cream containing 3% lauromacrogols and 5% urea, commonly used to treat atopic dermatitis. It has not been studied in CKD-aP to date.
Methods
UNASSIGNED
Adult haemodialysis patients were randomised 1:1 to apply Balneum Plus or E45 (Reckitt Beckiser, Slough, UK) to compare the active ingredients of lauromacrogol and urea with a control cream. Itch was defined as three episodes of itching during the last 2 weeks, appearing a few times a day, lasting a few minutes and troubling the patient [1]. Patients with other causes of itch, e.g. eczema and liver disease, were excluded. The primary outcome was a reduction in itch as measured by the visual analogue scale (VAS) score at 4 weeks and analysed using an analysis of covariance approach.
Results
UNASSIGNED
A total of 314 patients were screened and 58 patients were randomised, 29 in each group. Three patients dropped out in each group. The median baseline VAS scores were 6.5 [interquartile range (IQR) 4.4-8.0] in the Balneum Plus group and 6.3 (IQR 5.1-7.3) in the E45 group. After 4 weeks, VAS scores decreased to 2.6 (IQR 0.9-4.5) and 2.0 (IQR 0.5-4.8) in the Balneum Plus and E45 groups respectively (
Conclusion
UNASSIGNED
This is the first randomised controlled study of two different emollients for the treatment of CKD-aP and is a negative study. We found no significant difference in itch scores between Balneum Plus and E45.
Identifiants
pubmed: 37529648
doi: 10.1093/ckj/sfad066
pii: sfad066
pmc: PMC10387385
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1307-1315Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the ERA.
Déclaration de conflit d'intérêts
None declared.
Références
Kidney Med. 2020 Nov 21;3(1):42-53.e1
pubmed: 33604539
Br J Dermatol. 2011 Sep;165(3):633-9
pubmed: 21668425
Am J Kidney Dis. 2017 Nov;70(5):638-655
pubmed: 28720208
Cochrane Database Syst Rev. 2020 Dec 7;12:CD011393
pubmed: 33283264
Clin J Am Soc Nephrol. 2019 May 7;14(5):673-681
pubmed: 30975656
Clin Kidney J. 2021 Oct 14;14(Suppl 3):i8-i15
pubmed: 34987778
Curr Med Res Opin. 2005 Nov;21(11):1735-9
pubmed: 16307693
Nephron Clin Pract. 2009;113(3):c169-76
pubmed: 19672115
Acta Derm Venereol. 2001 May;81(2):108-11
pubmed: 11501646
Clin Kidney J. 2021 Oct 14;14(Suppl 3):i1-i7
pubmed: 34987777
Ther Apher Dial. 2004 Oct;8(5):419-22
pubmed: 15663539
J Eur Acad Dermatol Venereol. 2020 Oct;34(10):2368-2372
pubmed: 32170896
Can J Kidney Health Dis. 2020 Oct 15;7:2054358120954024
pubmed: 33117546
Curr Med Res Opin. 1997;13(9):529-37
pubmed: 9169255
Exp Dermatol. 2014 Dec;23(12):922-3
pubmed: 25265889
Acta Derm Venereol. 2019 Dec 1;99(13):1201-1209
pubmed: 31454051
Clin Cosmet Investig Dermatol. 2021 Aug 03;14:959-969
pubmed: 34377004
Clin Kidney J. 2021 Nov 09;15(3):484-499
pubmed: 35211305
Kidney Int Rep. 2020 May 08;5(9):1387-1402
pubmed: 32954065
Clin J Am Soc Nephrol. 2011 Apr;6(4):748-52
pubmed: 21258039
Clin J Am Soc Nephrol. 2017 Dec 7;12(12):2000-2007
pubmed: 28923831
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1813-21
pubmed: 24832095
Dermatol Ther. 2018 Nov;31(6):e12692
pubmed: 30246910
Toxins (Basel). 2021 Jul 28;13(8):
pubmed: 34437400
Nephrol Dial Transplant. 1996 Oct;11(10):2031-6
pubmed: 8918718
Pharmaceuticals (Basel). 2022 Jul 28;15(8):
pubmed: 36015082
Clin Kidney J. 2021 Dec 24;14(Suppl 3):i23-i31
pubmed: 34987780
J Dermatolog Treat. 2009;20(2):76-81
pubmed: 18821119
Clin Kidney J. 2021 Oct 14;14(Suppl 3):i16-i22
pubmed: 34987779
J Dermatolog Treat. 2003 Sep;14(3):190-1
pubmed: 14522633
Skin Pharmacol Physiol. 2013;26(2):108-18
pubmed: 23549137
Nephrol Dial Transplant. 2010 Apr;25(4):1251-7
pubmed: 19926718
J Bras Nefrol. 2012 Jun;34(2):148-52
pubmed: 22850916